Monthly Archives: May 2014

Benitec Start Dosing With TT-034 In Patients With Hepatitis C

Sydney Australia, 29 May 2014: RNAi based therapeutics company, Benitec Biopharma Limited (ASX: BLT, BNIKF in USA) is pleased to announce that it has dosed the first patient in its ‘first in man’, Phase I/IIa clinical trial for TT-034, a ddRNAi&based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection.

Benitec Biopharma’s CEO and Managing Director, Peter French said, “The commencement of this clinical trial of TT-034 represents a landmark in the Company’s history. The trial is the first time Benitec’s gene silencing technology, ddRNAi, … Read more

Benitech failing to deliver – 23 May 2014 ?

On 22 May, European Patent court at the Hague overturned Benitec’s cardinal DNA-directed RNA patent for the European Union. Benitec will hereafter have to pay to use Mick Graham’s work in the EU, and there will not get exclusive rights to it.

It would be difficult to convey concisely how disappointing and bad this is for Benitec shareholders, especially in view of other events taking place. This event is very counter to guidance previously given by Benitec management, who have stated that Benitec’s global patent estate was secure. Since the